Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?

Two medications. Both GLP-1 receptor agonists. Both FDA-approved for weight loss. Both producing results that have reshaped how providers think about treating obesity. So which one is right for you?

The answer depends on your biology, not a headline. At Med Matrix, we run a 100-biomarker lab panel before prescribing either medication. That panel tells us whether semaglutide, tirzepatide, or a different approach altogether makes the most sense for your body.

How Semaglutide Works

Semaglutide targets the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally after eating. It signals fullness, slows stomach emptying, and helps regulate blood sugar.

When you take semaglutide, that signal gets amplified. Appetite drops. The constant "food noise" quiets down. Patients describe it as the first time they can eat a normal portion and feel satisfied. Kim, one of our patients, put it this way: the food noise just went away.

Brand names you may recognize: Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). Same molecule, different dosing and indication. There is also Rybelsus, an oral tablet form of semaglutide. You can read more about how semaglutide works in the body.

Clinical trials (STEP program) showed patients on semaglutide lost an average of 15% of their body weight over 68 weeks. For someone at 250 pounds, that is roughly 37 pounds.

How Tirzepatide Works

Tirzepatide does what semaglutide does, plus more. It activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone involved in insulin secretion and fat metabolism. This dual agonist mechanism is why tirzepatide is sometimes called a dual incretin mimetic.

By hitting both receptors, tirzepatide may produce greater appetite suppression and improved metabolic signaling in some patients. Brand names: Mounjaro (diabetes) and Zepbound (weight management).

In the SURMOUNT trials, tirzepatide produced weight loss of up to 22.5% of body weight at the highest dose over 72 weeks. That is roughly 50% more weight loss than semaglutide achieved in its comparable trials. For a deeper look at tirzepatide as a peptide and how its dual receptor action works, read our tirzepatide peptide guide.

Anthony lost 37 pounds on tirzepatide at Med Matrix. But the medication was only one piece. His team also discovered he was a point away from pre-diabetes, something no previous doctor had caught.

Side-by-Side Comparison

Here is how the two medications compare on the factors patients ask about most:

• Receptors: Semaglutide targets GLP-1 only. Tirzepatide targets GLP-1 and GIP.
• Average weight loss: Semaglutide ~15% body weight (STEP trials). Tirzepatide ~20-22.5% body weight (SURMOUNT trials).
• Dosing: Semaglutide goes up to 2.4 mg weekly. Tirzepatide goes up to 15 mg weekly.
• Administration: Both are once-weekly subcutaneous injections. Semaglutide also has an oral form (Rybelsus).
• Brand names: Semaglutide = Ozempic, Wegovy, Rybelsus. Tirzepatide = Mounjaro, Zepbound.
• FDA approval: Both approved for type 2 diabetes and chronic weight management.

Side Effects: Semaglutide vs Tirzepatide

Both medications share similar side effects, primarily gastrointestinal:

• Nausea (most common, usually worst in the first few weeks)
• Constipation or diarrhea
• Stomach discomfort
• Reduced appetite (this is the intended effect, but it can feel intense initially)

Tirzepatide tends to have similar rates of nausea but may cause slightly more GI effects at higher doses due to the dual-receptor mechanism. Some patients actually tolerate tirzepatide better because the GIP pathway appears to buffer the GI response. Both medications are titrated gradually, starting at a low dose and increasing over weeks, specifically to minimize these effects.

At Med Matrix, your provider monitors your labs throughout the process. If nausea lingers or your metabolic markers shift unexpectedly, your protocol gets adjusted. You are not left guessing. For a deeper look at what to expect, read our guide on semaglutide and tirzepatide side effects.

Cost: Semaglutide vs Tirzepatide

Cost is one of the most common questions we hear. Here is the reality:

• Brand-name semaglutide (Wegovy) runs roughly $1,300-$1,600/month without insurance.
• Brand-name tirzepatide (Zepbound) runs roughly $1,000-$1,200/month without insurance.
• Compounded versions of both medications are available at significantly lower cost through 503B-registered compounding pharmacies. Availability depends on FDA shortage status, which changes.

At Med Matrix, full onboarding (labs, InBody scan, 60-minute provider consultation) runs approximately $1,200 to $1,500. Medication costs are separate and vary by protocol. We accept HSA, FSA, CareCredit, and all major cards. New patients receive a $100 voucher toward their first visit.

Switching from Semaglutide to Tirzepatide

Some patients start on semaglutide and switch to tirzepatide later. Common reasons we see:

• Weight loss has plateaued after several months on semaglutide
• GI side effects are persistent and not improving with dose adjustments
• The patient wants to try the dual-receptor approach for better metabolic signaling
• Insurance or cost changes make tirzepatide more accessible

Switching is not as simple as swapping one for the other. The dosing schedules are different, and your body may need a transition period. Your provider will typically start tirzepatide at the lowest dose (2.5 mg) regardless of where you were on semaglutide, then titrate based on your response and labs.

In our GLP-1 and weight loss podcast episode, our team discusses why tirzepatide is often preferred for patients who need stronger metabolic support, including its anti-inflammatory properties and how fiber can trigger natural GLP-1 production as a complement to either medication.

The Part Most Clinics Skip

A prescription by itself is incomplete. Stubborn weight often has drivers that no GLP-1 medication addresses on its own: thyroid dysfunction, insulin resistance, cortisol imbalance, sex hormone shifts, chronic inflammation, nutrient deficiencies.

If your thyroid is underactive and nobody catches it, you will lose some weight on semaglutide and plateau. If insulin resistance is the primary driver, tirzepatide's GIP activity might give you an edge, but you still need the metabolic picture to confirm.

We test over 100 biomarkers before prescribing. Thyroid panel (TSH, free T3, free T4, reverse T3, antibodies). Fasting insulin and glucose. A1C. Full lipid panel with particle size. Inflammatory markers. Sex hormones. Metabolic markers. InBody 770 body composition scan.

That data tells your provider which medication to prescribe, what dosing schedule to use, and what other factors to address at the same time. This is the functional medicine approach to weight loss.

Which One Should You Choose?

There is no universal answer. Both medications work. The right choice depends on:

• Your metabolic profile (insulin resistance, A1C, fasting glucose patterns)
• Your health history and any existing conditions
• How your body responds to GLP-1 signaling
• Cost and availability (compounding pharmacy options may reduce the price gap)
• Your provider's clinical judgment based on your full lab panel

Some patients do better on semaglutide. Some respond more strongly to tirzepatide. Some start on one and switch. The point is that the decision should come from data, not marketing.

What Happens at Med Matrix

Your first visit is a 30-minute testing appointment. We draw blood for a 100-biomarker panel and run an InBody 770 body composition scan. Your provider reviews everything before your one-hour consultation, where you go over every result together and decide on a plan.

If a GLP-1 medication fits your profile, your provider prescribes it as part of a medical weight loss protocol that includes nutrition guidance, body composition tracking, and ongoing lab monitoring. Follow-up visits track your progress and adjust your plan as your body responds.

FAQs

Is tirzepatide better than semaglutide?

Tirzepatide showed greater average weight loss in clinical trials (22.5% vs 15% body weight). But "better" depends on your body. Some patients respond more strongly to semaglutide. The right answer comes from your lab results and health history, not averages.

Can you switch from semaglutide to tirzepatide?

Yes. Patients switch for plateau, side effects, or provider recommendation. Your provider will restart tirzepatide dosing at 2.5 mg and titrate up based on your response.

What is the difference between Mounjaro and Zepbound?

Same molecule (tirzepatide), different indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Your provider chooses based on your diagnosis and insurance coverage.

How much does tirzepatide cost vs semaglutide?

Brand-name pricing is similar ($1,000-$1,600/month without insurance). Compounded versions can be significantly cheaper. At Med Matrix, medication cost is separate from the onboarding labs and consultation ($1,200-$1,500).

Which has fewer side effects?

Side effect rates are comparable. Some patients tolerate tirzepatide better because the GIP receptor may buffer GI symptoms. Others do better on semaglutide's single-receptor approach. Slow dose titration reduces side effects for both.

Get Your Free Guide + $100 Voucher and take the first step toward finding the right approach for your body.